Shang-Hung Chen

Publication Activity (10 Years)

Years Active: 2019-2024
Publications (10 Years): 4

Top Topics

Combination Therapy

Liquid Chromatography

Simultaneous Determination

Top Venues

Cancer medicine

This page only lists publications with an associated author ORCID identifier.

Publications

Shang-Hung Chen, Ka-Po Tse, Yen-Jung Lu, Shu-Jen Chen, Yu-Feng Tian, Kien Thiam Tan, Chien-Feng Li
Comprehensive genomic profiling and therapeutic implications for Taiwanese patients with treatment-naïve breast cancer. Cancer medicine 13 (12) (2024)
Shang-Hung Chen, Ka-Po Tse, Yen-Jung Lu, Shu-Jen Chen, Yu-Feng Tian, Kien Thiam Tan, Chien-Feng Li
Comprehensive genomic profiling and therapeutic implications for Taiwanese patients with treatment-naïve breast cancer. Cancer medicine 13 (12) (2024)
Shang-Hung Chen, Ka-Po Tse, Yen-Jung Lu, Shu-Jen Chen, Yu-Feng Tian, Kien Thiam Tan, Chien-Feng Li
Comprehensive genomic profiling and therapeutic implications for Taiwanese patients with treatment-naïve breast cancer. Cancer medicine 13 (12) (2024)
Tzu-Yu Lin, Hsiu-Han Chan, Shang-Hung Chen, Sailu Sarvagalla, Pai-Sheng Chen, Mohane Selvaraj Coumar, Siao Muk Cheng, Yung-Chieh Chang, Chun-Hui Lin, Euphemia Y Leung, Chun Hei Antonio Cheung
BIRC5/Survivin is a novel ATG12-ATG5 conjugate interactor and an autophagy-induced DNA damage suppressor in human cancer and mouse embryonic fibroblast cells. Autophagy 16 (7) (2019)